Ligand Pharmaceuticals Incorporated Common Stock LGND
i
Market dataready · fetched 2026-11-13T01:54:36.370Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T00:57:03.619130188Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T01:54:36.232235+00:00
Ligand Pharmaceuticals Incorporated Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 336.80 | 45.4% | 7.0% | 300.18 | 46.2% | 6.1% |
| 25Δ | 332.74 | 44.5% | 5.9% | 304.02 | 42.8% | 5.1% |
| 30Δ | 329.08 | 43.9% | 5.0% | 307.86 | 39.4% | 4.0% |
| 35Δ | 326.24 | 43.8% | 4.4% | 311.01 | 37.7% | 3.3% |
| 40Δ | 323.41 | 43.7% | 3.8% | 313.31 | 38.3% | 2.9% |
| 45Δ | 320.57 | 43.6% | 3.2% | 315.60 | 38.9% | 2.6% |
| 50Δ | 317.94 | 43.4% | 2.8% | 317.90 | 39.4% | 2.2% |
| 55Δ | 315.37 | 43.3% | 2.4% | 320.23 | 40.0% | 1.9% |
| 60Δ | 312.79 | 43.1% | 2.0% | 322.90 | 40.2% | 1.6% |
| 65Δ | 310.22 | 42.9% | 1.6% | 325.58 | 40.5% | 1.3% |
| 70Δ | 307.36 | 42.5% | 1.4% | 328.26 | 40.7% | 1.0% |
| 75Δ | 304.48 | 42.0% | 1.1% | 331.49 | 41.3% | 0.8% |
| 80Δ | 301.61 | 41.6% | 0.8% | 335.73 | 42.5% | 0.6% |
20Δ
- Pseudo strike
- 336.80
- IV
- 45.4%
- B/E move
- 7.0%
- Pseudo strike
- 300.18
- IV
- 46.2%
- B/E move
- 6.1%
25Δ
- Pseudo strike
- 332.74
- IV
- 44.5%
- B/E move
- 5.9%
- Pseudo strike
- 304.02
- IV
- 42.8%
- B/E move
- 5.1%
30Δ
- Pseudo strike
- 329.08
- IV
- 43.9%
- B/E move
- 5.0%
- Pseudo strike
- 307.86
- IV
- 39.4%
- B/E move
- 4.0%
35Δ
- Pseudo strike
- 326.24
- IV
- 43.8%
- B/E move
- 4.4%
- Pseudo strike
- 311.01
- IV
- 37.7%
- B/E move
- 3.3%
40Δ
- Pseudo strike
- 323.41
- IV
- 43.7%
- B/E move
- 3.8%
- Pseudo strike
- 313.31
- IV
- 38.3%
- B/E move
- 2.9%
45Δ
- Pseudo strike
- 320.57
- IV
- 43.6%
- B/E move
- 3.2%
- Pseudo strike
- 315.60
- IV
- 38.9%
- B/E move
- 2.6%
50Δ
- Pseudo strike
- 317.94
- IV
- 43.4%
- B/E move
- 2.8%
- Pseudo strike
- 317.90
- IV
- 39.4%
- B/E move
- 2.2%
55Δ
- Pseudo strike
- 315.37
- IV
- 43.3%
- B/E move
- 2.4%
- Pseudo strike
- 320.23
- IV
- 40.0%
- B/E move
- 1.9%
60Δ
- Pseudo strike
- 312.79
- IV
- 43.1%
- B/E move
- 2.0%
- Pseudo strike
- 322.90
- IV
- 40.2%
- B/E move
- 1.6%
65Δ
- Pseudo strike
- 310.22
- IV
- 42.9%
- B/E move
- 1.6%
- Pseudo strike
- 325.58
- IV
- 40.5%
- B/E move
- 1.3%
70Δ
- Pseudo strike
- 307.36
- IV
- 42.5%
- B/E move
- 1.4%
- Pseudo strike
- 328.26
- IV
- 40.7%
- B/E move
- 1.0%
75Δ
- Pseudo strike
- 304.48
- IV
- 42.0%
- B/E move
- 1.1%
- Pseudo strike
- 331.49
- IV
- 41.3%
- B/E move
- 0.8%
80Δ
- Pseudo strike
- 301.61
- IV
- 41.6%
- B/E move
- 0.8%
- Pseudo strike
- 335.73
- IV
- 42.5%
- B/E move
- 0.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 38.80% | |
| 38.63% | |
| 38.63% | |
| 39.62% | |
| 39.81% | |
| 40.45% | |
| 40.39% | |
| 39.93% | |
| 36.77% | |
| 38.43% |
Biotechnology
LITS
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company is headquartered in San…
More →LKFT
Lakefront Biotherapeutics NV (LKFT) is an innovative biopharmaceutical company focused on addressing significant unmet medical needs in oncology and infectious diseases through…
More →LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. The company is headquartered in Bala Cynwyd,…
More →LXEO
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company is headquartered in New York, New York.
More →LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in…
More →LYEL
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South…
More →